Improve the mechanism of biotechnology advancement

In recent years, due to the lack of a clear judgment on the prospects of the Chinese medicine market, Chinese medicine is gradually declining in China, while the “foreign Chinese medicine” in Japan, Korea, Southeast Asia, Europe and other countries and regions has entered the Chinese market. According to statistics, nearly half of domestic Chinese medicine is controlled by foreign capital.

On January 6, the Chinese government issued the “Development Plan for Biological Industry” (hereinafter referred to as the “Planning”) recently issued by the State Council. According to the reporter, the "Planning" subdivided the bio-industry into seven key areas: biomedicine, biomedical engineering, bio-agriculture, bio-manufacturing, bio-energy, bio-environmental protection, and biological services. According to its goals, the bio-industry will develop into a pillar industry of the national economy in 2020. The reporter of the “Medicine Economic News” interviewed industry experts at the first time and analyzed the relevant contents of the “Planning”.

"Planning" clearly puts forward a plan of action for the standardization of traditional Chinese medicines to improve the standardization level of the Chinese medicine industry and promote the internationalization of Chinese medicine.

In an interview with this reporter, Mr. Ruan Guozhong, director of the Center for the Translation of Chinese Medical Science and Technology Achievements, said that the standardization of the construction of Chinese herbal medicine bases is very necessary. The use of biotechnology to promote the selection and breeding of fine varieties of authentic Chinese herbal medicines and pollution-free cultivation can promote the resources of Chinese medicine. To protect and sustainably use, or to create a batch of traditional Chinese medicine standardization demonstration industry chain from raw materials to medicines.

At the same time, the "Planning" also proposed an optimization review and approval procedure, formulate and improve the mechanism for the inclusion of biotechnological drugs in the medical insurance product catalog, improve the generic name drug price formation mechanism and the drug bidding mechanism, and improve the quality standards and medication safety of traditional Chinese medicines. Research and formulate priority policies such as medical insurance catalogs to ensure the implementation of the Plan.

Compared with the "Eleventh Five-Year Plan" for the development of bio-industries, biomedical and biological services are listed separately. The "Planning" places the biomedical engineering and bio-service industries into 7 key areas, and the bio-service industry has become a new term.

The "Planning" pointed out that during the "12th Five-Year Plan" period, efforts will be made to promote the development of high-performance medical equipment, accelerate the industrialization of high value-added planting materials and products, and vigorously develop new types of in vitro diagnostic products. By 2015, the annual output value of the biomedical engineering industry will reach 400 billion yuan, breaking through a number of core technologies and fostering a number of high-end biomedical engineering manufacturing companies.

"In recent years, China's medical equipment industry has developed rapidly, but high-performance medical equipment still mostly originates from imports. The absence of high-end medical equipment in China and the high prices of imported medical equipment have, to some extent, boosted medical expenses." A well-known securities analyst stated that “Planning” separates the biomedical engineering from the biopharmaceutical industry to enhance its position in the bio-industry and contributes to the application of biotechnology in R&D and production of high-performance medical equipment. To promote the advanced development of the advanced medical device industry chain and improve the market competitiveness of domestic products, the overall cost of diagnosis and treatment may drop to some extent."

As a new type of service industry, accompanied by the continuous development of biotechnology, biological services were first described in Planning. It is a cross-cutting field between the bio-industry and the modern service industry. It includes both new types of services provided by biotechnology and other modern scientific and technological means for social development and improvement of living, and also includes the characteristics of the bio-industry itself and provides for the development of the bio-industry itself. Special technical services. "Planning" predicts that by 2015, the annual output value of the bio-service industry will reach 150 billion yuan, and there will be a large number of bio-service large enterprises with advanced international standards.

Li Qing, director of the Medical and Health Science and Technology Development Research Center of the Ministry of Health, said in an interview with a reporter from the “Medicine Economics” that one of the highlights of the “planning” was the elaboration of the new field of bioservices. Compared with the traditional physical manufacturing industry, biological services are more characteristic of strategic emerging industries: lower energy consumption, less pollution, and higher technological content. The development of the biological service industry is conducive to the demand of the biological industry to explore the market, enhance the industrial level, and expand the industry. Space for development.

According to Li Qing, before the “Eleventh Five-Year Plan”, the bio-service industry had just emerged. Therefore, it was only briefly mentioned in the “Eleventh Five-Year Plan” for the development of bio-industries. After this, the bio-service industry started to take shape. In the future, it will become a new economic growth point.

However, the current development of the bio-service industry is not balanced, and some of the sectors are not yet mature. Li Qing explained that in terms of technology outsourcing services, China’s CRO (contract research organization) has developed for many years. Domestic companies also have their own characteristics in the international outsourcing market, and they have created some listed companies and have formed industrialization, but other links, such as Intermediary services in terms of policies, laws, etc. are done by the government, and market-oriented companies have only just begun.

According to Lu Guozhong, the long-term development of the biomanufacturing industry must have the support of its supporting biological service system. The "biology service industry" was first proposed in the "planning", which reflects the country's determination to build a complete bio-industry chain structure. "However, the specific areas of biological services in the "planning" need to be clarified. If the relevant contents mentioned are all attributed to biological services, the output value in 2015 will exceed 150 billion yuan." Li Guozhong added: "I think Shanghai's recent production The new formulation of sex service industry is good, and it can be differentiated from the consumer service industry, or it can be used as a reference for biological services in the bio-industry."

In the view of enterprises, with the "planning", more support policies need to be introduced. Executives of a bio-services company stated that the existing policies are formulated for the entire bio-industry, and that the type of business within the industry varies greatly, and policies need to be refined. In addition to policies, the formulation of industry rules and standards for bioservices should also be put on the agenda of government and industry companies.